I

INFINIUM PHARMACHEM LTD

INFINIUMNSE
Market snapshot · 2026-08-10 21:04 UTC

218.05

₹-1.45 (-0.66%)

MARKET CAP

STOCK P/E

52W HIGH

₹224.00

52W LOW

₹214.50

BOOK VALUE

EPS

ROE

SECTOR

Healthcare

DEBT/EQUITY

VOLUME

9,500

P/B RATIO

PEG RATIO

Sector

Healthcare

Themes

Healthcare
₹219.05₹218.80₹218.55₹218.30₹218.05VolumeAug '26

AI Summary

✦ Clartha

Forecast

Analyst targets, estimate history, and probabilistic forward ranges for INFINIUM.

Coverage check

Price Forecast

Current
₹218.05
High Target
Median Target
Low Target
Price history (1Y)
Analyst target range

Probabilistic Range

Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.

Time horizonRange ()Probability
3M₹170.44 - ₹251.6080%
6M₹149.32 - ₹259.0180%
12M₹120.16 - ₹261.8480%
Realized vol: +30.4% · Drift: -16.0%

Revenue Forecast

₹ Cr
Mar '26Current₹84.0
Sep 2026 ETrend estimate range
High₹98.2Base₹90.9Low₹83.6
Sep '24: ₹71.0 · Mar '25: ₹66.0 · Sep '25: ₹73.0 · Mar '26: ₹84.0 · Sep '26: ₹90.9 · Dec '26: ₹104.6
Sep '24Mar '25Sep '25Mar '26Sep '26 EDec '26 E71.066.073.084.090.9104.6
PastCurrentTrend estimate: Low / Base / High

EPS Forecast

₹ / share
Mar '26Current₹3.45
Sep 2026 ETrend estimate range
High₹2.49Base₹2.22Low₹1.95
Sep '24: ₹2.85 · Mar '25: ₹2.89 · Sep '25: ₹2.98 · Mar '26: ₹3.45 · Sep '26: ₹2.22 · Dec '26: ₹2.57
Sep '24Mar '25Sep '25Mar '26Sep '26 EDec '26 E2.852.892.983.452.222.57
PastCurrentTrend estimate: Low / Base / High
Analyst price target unavailable from FMP/yfinance. Analyst recommendation consensus unavailable from FMP/yfinance. Valuation pillar unavailable from supplied valuation. Analyst pillar unavailable from FMP/yfinance.
Market Intelligence

Multi-factor synthesis of 5 key dimensions

Overall Outlook
Neutral
55%
Analyst Consensus
Unavailable

Analyst coverage unavailable

Mean upsideNot available

Fundamentals

Moderate

Fundamentals institutional score is 57 using growth durability 56.8.

Valuation

Unavailable

No valid valuation metrics were supplied.

Analyst Consensus

Unavailable

No usable analyst target or recommendation data was available.

Technical Structure

Mixed Momentum

Technicals institutional score is 52 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.

Market Sentiment

Unavailable

This data source has not been supplied for the decision payload.

Signal Summary

Market intelligence remains Neutral. Available evidence provides partial support, while technical structure remain considerations.

Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.

Fundamentals ModerateTechnical Structure Mixed Momentum

Key Data Points

Mean Target PriceUnavailable
Mean UpsideNot available
Technical Score52%
Fundamental Score57%
Data CoverageMedium

Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.

Valuation Metrics

Forward Valuation Outlook

Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.

Historical valuation metrics are unavailable for this ticker right now.

Peers & Comparison

Sector: Healthcare

Healthcare Peers8 peers
Avg P/E: 24.4x
CompanyRev. GrowthMarginP/Evs Avg52W Perf.
15.4x
Undervalued
-37% vs avg
7.3x
Undervalued
-70% vs avg
68.6x
Premium
+181% vs avg
KRMAYURVED
KRMAYURVEDHealthcare
MEDISTEP
MEDISTEPHealthcare
CURIS
CURISHealthcare
SUNREST.NS,0P0001RTOB,0
SUNRESTHealthcare
6.4x
Undervalued
-74% vs avg
WHY THESE PEERS

Comparable-scale peer data is limited — showing nearest stored business/industry peers instead of an empty comparison.

Financials

Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.

Latest revenue

₹84 CrMar 2026

Latest net profit

₹5.00 CrMar 2026

Latest EPS

₹3.45Mar 2026

Net margin

10.0%Mar 2026

Performance

Bars show revenue and net profit. The line shows net margin.

Rs crore + margin %
Q4 '25Q1 '26Q2 '26Q3 '26Q4 '260.0%4.0%8.0%12.0%16.0%0.00 Cr25 Cr50 Cr75 Cr100 Cr
  • Revenue
  • Net income
  • Net margin %

Earnings

Revenue is shown in crores. EPS is rupees per share.

Rs crore + Rs/share
Q4 '25Q1 '26Q2 '26Q3 '26Q4 '260.00 Cr25 Cr50 Cr75 Cr100 Cr₹0₹1₹2₹3₹4
  • Revenue
  • EPS

Revenue to profit conversion

Bridge from operating numbers to profit for the latest reported period.

Rs crore
RevenueExpensesDepreciationOtheradjustmentsOperatingprofitOther incomeInterestOtheradjustmentsProfitbefore taxTax & otherNet Profit0.00 Cr25 Cr50 Cr75 Cr100 Cr

Latest reported period: Mar 2026

Debt level and coverage

Debt, cash and free cash flow compared on the same crore scale.

Rs crore
Annual view
Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-60 Cr0.00 Cr60 Cr120 Cr180 Cr
  • Debt
  • Free cash flow
  • Cash & equivalents

Results

MetricSep 2022Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026
Sales +58517271667384
Expenses +51416464576476
Operating Profit81087898
OPM %13%19%11%10%13%12%10%
Other Income +1011101
Interest1111211
Depreciation0111211
Profit before tax7876667
Tax %25%25%26%29%25%26%26%
Net Profit +5654555
EPS in Rs4.904.403.562.852.892.983.45
Raw PDF

All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).

Shareholding Pattern

HolderSep 2024Nov 2024Mar 2025Sep 2025Mar 2026
Promoters +73.05%65.24%65.24%59.91%64.91%
DIIs +0.02%0.21%
Public +26.95%34.76%34.76%40.07%34.87%
Others0.01%
Mar 2026
Promoters +
DIIs +
Public +
Others

Events Timeline

Certificate under SEBI (Depositories and Participants) Regulations, 2018

Jul 13, 2026PDFCompany Reports Open

Disclosure under SEBI Takeover Regulations

Jun 23, 2026PDFCompany Reports Open

Updates

Jun 23, 2026PDFCompany Reports Open

Outcome of Board Meeting

May 29, 2026PDFCompany Reports Open

General Updates

May 20, 2026PDFCompany Reports Open